Well, I suppose given the success of In Silico Medicine, after many years of grit and bootstrapping, it was inevitable to see other groups try the same model and find willing sources of funding.
If these folk apply their technology to discovering senolytics and cross-link breakers, then great. If they apply it to finding mTOR inhibitors and geroprotectors, not so great.
There is a fork in the road for interventions in aging: one path leads to damage repair (e.g. senolytics to remove senescent cells, AGE-breakers to remove cross-links), the other to tinkering with metabolism in its damaged state (e.g. mTOR inhibitors and other tools that force greater stress response mechanism activation, the same thing that happens in calorie restriction and exercise). The former offers cost-effective rejuvenation of the old, the latter offers an expensive path to marginal slowing of aging and little benefit for people already old.
